Reviva Pharmaceuticals Secures Average Price Target of $3.33

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) received a consensus rating of “Moderate Buy” from eight research firms currently monitoring the company. According to MarketBeat, one analyst issued a sell recommendation, while seven analysts favor a buy recommendation. The average twelve-month target price among these brokerages is set at $3.33.

Analysts have been actively discussing Reviva Pharmaceuticals in recent weeks. On December 23, 2023, HC Wainwright reaffirmed a “buy” rating with a target price of $4.00. In a contrasting move, Wall Street Zen elevated Reviva from a “sell” to a “hold” rating on December 27. Weiss Ratings maintained a “sell (e+)” rating on October 8, while D. Boral Capital also reiterated a “buy” rating with a price target of $2.00 on the same date as HC Wainwright’s assessment. Additionally, Chardan Capital restated their “buy” rating and set a target of $2.00 on January 5, 2024.

Reviva Pharmaceuticals experienced a decline of 3.1% in its stock price recently. The company reported its quarterly earnings on November 13, 2023, revealing earnings per share of ($0.06), surpassing the consensus estimate of ($0.11) by $0.05. Analysts predict that Reviva will record an earnings per share of (-0.97) for the current fiscal year.

Institutional Investors Increase Stake in Reviva

Recent trading activity reflects a shift among institutional investors regarding Reviva Pharmaceuticals. Armistice Capital LLC acquired a new position in the company during the second quarter for approximately $1,026,000. Similarly, 683 Capital Management LLC invested $381,000 in Reviva during the same period.

Moreover, Persistent Asset Partners Ltd expanded its stake in Reviva by 300%, now holding 641,174 shares worth roughly $244,000 after adding an additional 480,864 shares. Millennium Management LLC increased its holdings by 15%, now owning 1,711,221 shares valued at $631,000 following a purchase of 223,178 shares. Lido Advisors LLC also entered into a new position during the third quarter, investing $37,000.

Overall, hedge funds and other institutional investors hold approximately 63.18% of Reviva Pharmaceuticals’ stock, indicating a significant interest in the company among major market players.

About Reviva Pharmaceuticals

Founded in 2002 and headquartered in Coral Gables, Florida, Reviva Pharmaceuticals is a specialty pharmaceutical company dedicated to the acquisition, development, and commercialization of prescription drug products in the United States and select international markets. The firm focuses on under-promoted, off-patent pharmaceuticals, aiming to enhance patient compliance and therapeutic outcomes through novel dosage forms. Reviva’s core activities include identifying FDA-approved drug candidates, developing formulations for niche patient populations—such as children and those with orphan indications—and supporting regulatory filings.

This information provides valuable insights into the current market position of Reviva Pharmaceuticals and reflects the ongoing interest from both analysts and investors in this evolving company.